Enanta's New Drug Offers Hope for Chronic Allergy and Immune Diseases

WATERTOWN, Mass. – February 10, 2026 – Enanta Pharmaceuticals, a biotech firm known for its pivotal role in developing a leading hepatitis C cure, is now targeting a new frontier: the complex world of immunological diseases. The company is set to present compelling preclinical data for its novel drug candidate, EDP-978, at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, signaling a potential paradigm shift in treating a range of chronic, mast cell-driven conditions.

Later this month, researchers will unveil two posters detailing the discovery and promising profile of EDP-978, an oral, highly selective KIT inhibitor. The findings represent a significant step for Enanta's strategic expansion into immunology and offer a glimmer of hope for millions of patients suffering from debilitating Type 2 immune diseases like chronic urticaria (hives), severe asthma, and atopic dermatitis (eczema).

A New Strategy for an Old Foe: Targeting Mast Cells

Type 2 immune diseases are a group of chronic inflammatory conditions characterized by an overactive immune response to often harmless triggers. This category includes allergic asthma, eczema, and chronic rhinosinusitis, which collectively affect a substantial portion of the global population. A key player at the center of this inflammatory cascade is the mast cell.

Mast cells are immune sentinels located in tissues that interface with the external environment, such as the skin, lungs, and gut. When activated, they release a potent cocktail of inflammatory mediators, including histamine and tryptase, which drive the familiar and often distressing symptoms of allergic reactions. For many patients, the battle is relentless. In chronic urticaria, for example, more than 50% of individuals do not find relief with standard-of-care H1-antihistamines, even at higher doses.

Current treatments, including powerful injectable biologics, have revolutionized care for many but still have limitations. They often target downstream inflammatory pathways or molecules, rather than addressing the hyperactive mast cells themselves. Enanta's EDP-978 proposes a different approach: go directly to the source.

The drug is a KIT inhibitor. KIT is a receptor tyrosine kinase essential for the survival, proliferation, and activation of mast cells. By blocking the KIT signaling pathway, EDP-978 is designed to reduce the number of mast cells and prevent their activation. This strategy has the potential to provide a more fundamental, disease-modifying effect compared to therapies that only manage symptoms.

Enanta's Strategic Pivot into Immunology

The move into immunology marks a significant and deliberate diversification for Enanta Pharmaceuticals. The company built its reputation and financial strength on its expertise in virology, co-discovering glecaprevir, a protease inhibitor that is a key component of AbbVie's blockbuster hepatitis C virus (HCV) treatment, MAVYRET®/MAVIRET®. The steady stream of royalties from this success has provided the company with a robust financial foundation, which it is now leveraging to build a new therapeutic franchise.

As of late 2025, Enanta reported a strong cash position of approximately $241.9 million, which it projects will fund its operations into 2029. This financial runway is crucial for the capital-intensive process of drug development. While the company continues to pursue treatments for viral infections like RSV, its increasing R&D investment in immunology underscores a long-term strategic shift.

EDP-978 is the vanguard of this new pipeline, but it is not alone. Enanta is also advancing a STAT6 inhibitor (EPS-3903) targeting the IL-4/IL-13 pathway for atopic dermatitis and an even earlier-stage MRGPRX2 inhibitor program for other inflammatory diseases. This multi-pronged approach demonstrates a deep commitment to becoming a leader in developing oral, small-molecule drugs for a range of inflammatory and immunological conditions with high unmet need.

Preclinical Promise and a Crowded Field

The two presentations at the AAAAI meeting are expected to provide the first detailed public look at EDP-978's potential. According to the company's announcements, one presentation will focus on the discovery of the drug as a potent and selective KIT inhibitor, while the second will highlight its favorable pharmacokinetic profile, demonstrating the potential for convenient once-daily oral dosing in humans.

Information released by Enanta ahead of the conference suggests EDP-978 exhibits nanomolar potency and high selectivity for KIT over other kinases, a critical attribute for minimizing off-target side effects. This selectivity is a key focus in a competitive landscape where other KIT inhibitors are also in development. Several existing and investigational KIT inhibitors, such as Novartis's Rydapt® and Blueprint Medicines' Ayvakit®, primarily target systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, often driven by a specific KIT mutation (D816V).

Enanta's strategy appears broader, aiming EDP-978 at a wider array of more common Type 2 immune diseases where mast cell activation, not necessarily accumulation or a specific mutation, is the central problem. The convenience of an oral, once-daily pill could also be a significant advantage over the injectable biologics that currently dominate the market for moderate-to-severe allergic diseases.

The Path Forward: From Lab Bench to Bedside

The promising preclinical data is the first of many hurdles EDP-978 must clear on the long road to becoming an approved therapy. Enanta has laid out an ambitious timeline, planning to file an Investigational New Drug (IND) application with regulators in the first quarter of 2026. This would pave the way for Phase 1 clinical trials in humans to evaluate the drug's safety, tolerability, and pharmacokinetics, with initial data anticipated by the fourth quarter of 2026.

If successful, EDP-978 could offer a transformative new option for patients. For individuals living with the daily burden of chronic hives, the constant threat of an asthma attack, or the persistent itch of eczema, a safe and effective oral therapy that targets the underlying cellular driver of their disease would be a major medical advance.

The market for such a drug is substantial, reflecting the millions of lives impacted by these chronic conditions. While the journey through clinical trials is fraught with uncertainty, the upcoming data presentation marks an important milestone, bringing a potential new class of therapy one step closer to the patients who need it most.